Loading quotes...
Forecast
| Buy |
1 |
| Hold |
0 |
| Sell |
0 |
News Go to news feed
SWK Holdings merges with Runway Growth Finance and is delisted by Nasdaq
SWK Holdings completed its merger with Runway Growth Finance and became a wholly owned subsidiary of Runway. Shareholders could elect to receive 1.7264 Runway common shares per SWK share or $20.59 in cash; Runway issued about 6.33 million shares and paid $173.54 million in cash. SWK filed for the delisting of its common shares and the suspension of SEC reporting obligations, all incumbent executives resigned, outstanding liabilities were fully repaid, and bond terms were adjusted to comply with the Investment Company Act. » More on de.investing.com
SWK Holdings: full repayment of loan to Elutia received after asset sale
SWK Holdings reports the full repayment of a loan to Elutia of USD 27.8 million, including principal, exit fees and accrued interest. The payment follows Elutia’s sale of its BioEnvelope business to Boston Scientific for USD 88.0 million. SWK says the receipt exceeds the loan’s net carrying value under GAAP and expects additional income from accelerated exit fees and the release of risk reserves. SWK also beat earnings expectations in Q2 2025 with earnings per share of USD 0.38. » More on de.investing.com
SWK Holdings beats Q2 earnings forecast, stock falls after results
SWK Holdings reported Q2 2025 EPS of $0.38, topping the $0.24 estimate. Cost cuts and asset sales produced GAAP pre-tax income of $4.6 million and net income of $3.5 million. The company paid $49 million in dividends, sharply reduced operating expenses and expects transitions in Q3 related to the sale of "Mod three." Despite the positive results, the stock fell in after-hours and pre-market trading, which investors say reflects concerns about the strategic realignment and regulatory risks. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | December 2025 | YoY |
|---|---|---|
| Revenue | 7.41m | - |
| Gross profit | 0 | - |
| Net profit | -16.52m | - |
| EBITDA | 35.8k | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €171.01m |
Number of shares | 12.1m |
52-week high/low | €15.92 - €11.15 |
| Dividends | No |
Beta | 0.30 |
P/E ratio | -43.47 |
PEG ratio | 0.28 |
P/B ratio | 1.30 |
P/S ratio | 6.52 |
Company profile
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Its product pipeline includes Ovarest, an oral leuprolide tablet to treat endocrine disease. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
| Name | SWK HOLDINGS DL-,001 |
| CEO | Jody. D Staggs |
| Headquarters | Dallas,
tx USA |
| Website | |
| Sector | Industrials |
| Industry | Ground Transportation |
| IPO | 23/09/1999 |
| Employees | 24 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | SWKH |